Biological age, not date of birth, can lead to a healthy long life

Summary: Accelerated biological and epigenetic aging are associated with lower odds of death in women aged 90 years and older.

A source: UCSD

A first-of-its-kind study of 1,813 older women shows that accelerated biological aging — accelerated epigenetic age — is associated with a reduced chance of living past age 90, as well as impaired physical and mental function. .

July 27, 2022 in the online edition JAMA Network OpenA multi-institutional team of researchers led by UC San Diego’s Herbert Wertheim School of Public Health and Human Longevity Sciences reports that epigenetic age acceleration can be used as a biomarker for healthy longevity and to assess functional and cognitive aging.

“Older people know very well that age is a number that does not indicate their health status. What if we had a way to measure our aging that could predict our chances of living a long and healthy life? In aging research, we call this the longevity of the individual,” said lead researcher Andrea LaCroix, Ph.D, MPH, Herbert Wertheim Distinguished Professor in the School of Public Health and Human Longevity.

Chronological age is based on the person’s birthday. Epigenetic age refers to the biological age of human cells, tissues and organ systems. If a person’s epigenetic age is greater than their chronological age, the person also has an epigenetic age, which is associated with a higher risk of cardiovascular disease, Parkinson’s disease, and other diseases.

Based on four different epigenetic “clocks” that measure biological aging, every five to eight years of epigenetic age acceleration reduces the chance of living to age 90 with intact mobility and cognitive function by 20% to 32%.

“Healthy longevity is important because the number of people age 90 and older in the United States is expected to quadruple from 1.9 million in 2016 to 7.6 million in 2050,” LaCroix said.

As part of a prospective study, the team analyzed data on the physical and cognitive health of 1,813 women who participated in the Women’s Health Initiative, which began in 1993 and was funded by the National Heart, Lung, and Blood Institute. The average age at death for participants in the Women’s Health Initiative was 90 years.

Of this group, 464 women lived to age 90 with intact mobility and cognitive function, 420 women lived to age 90 but had intact mobility and cognitive function, and 929 women died before age 90.

Study participants were between the ages of 70 and 72 and were followed until at least age 90 or until death. The association of epigenetic age-accelerating clocks with healthy longevity was found to be independent of other characteristics common among long-lived women with intact mobility and memory compared to those who did not survive to age 90, including those who were white or less white. baseline chronic conditions, higher education, non-smoking and walking several times a week.

Chronological age is based on the person’s birthday. Image is in the public domain

“Prior has shown that epigenetic age acceleration is associated with an increased risk of death, and several studies have observed slower age acceleration in people who live longer. But this is the first study to prospectively examine the relationship between slower age acceleration and survival to age 90 with preserved mobility and memory,” said the first author. Purva Jain, Ph.D., San Diego.

Jane graduated in December 2021 from the Epidemiology Department of the Joint Doctoral Program in Public Health at the Herbert Wertheim School of Public Health.

“Furthermore, our study can use epigenetic age acceleration to assess an individual’s risk of not achieving healthy longevity, which may lead to future public health interventions to counter poor health outcomes in the aging population,” Jain said.

Co-authors include: Brian Chen and John Alcaraz of UC San Diego; Alexandra Binder of UCLA and the University of Hawaii Cancer Center; Umberto Parada and Linda C. Gallo of San Diego State University; Steve Horvath, UCLA; Parveen Bhatti Cancer Control Research, BC Cancer; Eric A. Whitsell, James D. Stewart and Yoon Lee of the University of North Carolina at Chapel Hill; Christina Jordahl of the University of Washington; Andrea A. from Columbia University. Baccarelli; Lifan Hou of Northwestern University; and Jamie N. Justice of the Wake Forest School of Medicine.

Funding: Бул изилдөө улуттук саламаттыкты сактоо институттары тарабынан каржыланган: Улуттук жүрөк, өпкө, өпкө жана кан институту (HHSN268201600018C, HHSN26820160000001C, HHSN268201600003C, HHSN268201600004C, HHSN268201600004C, HHSN26820130000004C), Улуттук карылык институту Курчап турган чөйрөнү коргоо илимдеринин (R01 ES020836) жана Улуттук онкология институтунун (K01 CA234317), as well as the American Cancer Society (125299-RSG-13-100-01CCE), San Diego State University (U54 CA132384, U539), and UC San Diego (P30AG059299).

Disclosures: Binder reported receiving grants from the National Cancer Institute and scientific consulting fees from the Epigenetic Clock Development Fund during the conduct of the research.

Chen reported that he was a full-time employee and, in addition to his assigned work, held a patent for Foxo Technologies and held common stock in Illumina.

Horvath reports receiving grants from the National Institute on Aging, receiving personal payments outside of work assignments from the Epigenetic Clock Development Fund, and having a patent pending from the Epigenetic Clock Development Fund during the course of his research.

Jordahl reported receiving grants from the National Cancer Institute and personal payments from Bristol Myers Squibb during the course of his research.

This is about genetics and longevity research news

Author: Yadira Galindo
A source: UCSD
The connection: Yadira Galindo – UCSD
Photo: Image is in the public domain

Original research: Open access.
Andrea LaCroix et al. JAMA Network Open


Abstract

Analysis of epigenetic aging and healthy longevity among older US women

an important

Accelerated biological aging is associated with a decline in physical capacity and cognitive functioning, which is associated with an increased risk of morbidity and mortality.

See also

It shows a sad looking person

The goal

We investigated associations between the aging-related biomarker epigenetic age acceleration (EAA) and healthy longevity in older women.

Design, installation and participants

This cohort study was a secondary analysis of Women’s Health Initiative (WHI) participants who were eligible to live to age 90 by September 30, 2020. Participants are located in several centers. This study was limited to women with genome-wide DNA methylation data obtained from baseline blood samples from 3 WHI ancillary studies. Median (IQR) follow-up time from baseline was 21.6 (19.6–22.9) years and 21.4 (19.8–22.7) years for women surviving to age 90, compared with 13.2 ( 8.8-16.7) for women who survived to the age of 90. Data was analyzed from December 2020 to July 2021.

exposures

EAA rated 4 fixed “watches”: Horvath pantissue, Hannum, Pheno and Grim.

Main outcomes and measures

Using multinomial logistic regression, odds ratios (ORs) and 95% CIs were estimated for each of the 3 healthy longevity outcomes: survival to age 90 with intact mobility, survival to age 90 without intact mobility, and survival to age 90. .

Results

464 women among 1813 women (average [SD] according to initial indicators, 71.6 [3.5] years) 420 women (average) with intact mobility and cognitive function up to the age of 90. [SD] action at the initial state, 71.3 [3.2] year) and 929 women (average). [SD] action at the initial state, 70.2 [3.4] years) did not survive until the age of 90. Women who survived to age 90 with intact mobility and cognitive function compared with women who had poor health or survived to age 90 (eg, 143 women) [30.8%] 101 against women [24.0%] and 202 women [21.7%] 0 with a chronic condition).

AgeAccelHorvath (OR, 0.82; 95% CI, 0.69-0.96); P= .01), AgeAccelHannum (OR, 0.67; 95% CI, 0.56-0.80; P< .001), AgeAccelPheno (OR, 0.60; 95% CI, 0.51-0.72; P< .001) and AgeAccelGrim (OR, 0.68; 95% CI, 0.55-0.84; P< .001). ORs were similar for women surviving to age 90 with intact mobility and cognitive function (eg, AgeAccelHorvath: OR per 1 SD increase in EAA, 0.83; 95% CI, 0.71–0.98; P= .03) compared with women who survived to age 90.

Conclusions and relevance

These results suggest that EAA may be a valid biomarker associated with healthy longevity in older women and may be used for future functional and cognitive aging risk stratification and risk assessment. The results suggest that future research may focus on the potential of public health interventions to address EAA and its association with poor health outcomes, while reducing the burden of disease while increasing longevity.

Leave a Comment

Your email address will not be published.